Teva Historical Income Statement
| TEVA Stock | USD 15.49 0.20 1.27% |
Historical analysis of Teva Pharma income statement accounts such as Other Operating Expenses of 17.7 B, Ebit of 473.1 M, Cost Of Revenue of 4.8 B or Total Operating Expenses of 8.8 B can show how well Teva Pharma Industries performed in making a profits. Evaluating Teva Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Teva Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Teva Pharma Industries latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Teva Pharma Industries is a good buy for the upcoming year.
Teva |
About Teva Income Statement Analysis
Teva Pharma Industries Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Teva Pharma shareholders. The income statement also shows Teva investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Teva Pharma Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Teva Pharma Industries generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Teva Pharma Industries minus its cost of goods sold. It is profit before Teva Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Teva Pharma Industries. It is also known as Teva Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Teva Pharma Industries income statement and represents the costs associated with goods and services Teva Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most accounts from Teva Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. At present, Teva Pharma's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 1.1 B, whereas Total Revenue is forecasted to decline to about 9.7 B.
| 2023 | 2024 | 2025 (projected) | Interest Expense | 1.0B | 1.0B | 1.1B | Depreciation And Amortization | 1.2B | 1.3B | 1.4B |
Teva Pharma income statement Correlations
Click cells to compare fundamentals
Teva Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Teva Pharma income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 171.9K | 1.6B | 1.3B | 1.2B | 1.3B | 1.4B | |
| Interest Expense | 963M | 1.1B | 966M | 1.0B | 1.0B | 1.1B | |
| Total Revenue | 16.7B | 15.9B | 14.9B | 15.8B | 16.5B | 9.7B | |
| Gross Profit | 7.7B | 7.6B | 7.0B | 7.6B | 8.1B | 4.9B | |
| Other Operating Expenses | 13.6B | 12.8B | 12.2B | 12.7B | 16.8B | 17.7B | |
| Operating Income | 2.8B | 3.1B | 3.2B | 433M | (303M) | (287.9M) | |
| Ebit | (3.7B) | 3.1B | (2.2B) | 433M | 498.0M | 473.1M | |
| Ebitda | (2.1B) | 4.4B | (874M) | 433M | (303M) | (287.9M) | |
| Cost Of Revenue | 8.9B | 8.3B | 8.0B | 8.2B | 8.5B | 4.8B | |
| Total Operating Expenses | 4.7B | 4.5B | 4.3B | 4.5B | 8.4B | 8.8B | |
| Income Before Tax | (4.4B) | 658M | (3.1B) | (624M) | (1.3B) | (1.2B) | |
| Total Other Income Expense Net | (834M) | (1.1B) | (1.1B) | (1.1B) | (981M) | (1.0B) | |
| Net Income | (4.0B) | 417M | (2.4B) | (559M) | (1.6B) | (1.6B) | |
| Income Tax Expense | (168M) | 211M | (638M) | (65M) | 355M | 372.8M | |
| Research Development | 997M | 967M | 838M | 953M | 998M | 818.5M | |
| Selling General Administrative | 1.2B | 1.1B | 1.2B | 1.2B | 1.2B | 1.2B | |
| Net Income Applicable To Common Shares | (999M) | (4.0B) | 417M | (2.4B) | (2.1B) | (2.0B) | |
| Minority Interest | (109M) | 39M | 53M | 56M | 320M | 336M | |
| Selling And Marketing Expenses | 2.5B | 2.4B | 2.3B | 2.3B | 2.5B | 3.2B | |
| Net Income From Continuing Ops | (4.2B) | 447M | (2.4B) | (615M) | (2.0B) | (2.1B) | |
| Tax Provision | (168M) | 211M | (638M) | (7M) | 676M | 709.8M | |
| Net Interest Income | (963M) | (962M) | (966M) | (1.1B) | (1.1B) | (1.1B) | |
| Reconciled Depreciation | 1.6B | 1.3B | 1.3B | 1.2B | 1.1B | 1.2B | |
| Non Operating Income Net Other | (1.0B) | (835M) | (696M) | (1.0B) | (1.2B) | (1.3B) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (1.45) | Revenue Per Share | Quarterly Revenue Growth (0.05) | Return On Assets |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.